Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
about
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexityInterpretation of cytogenetic results in multiple myeloma for clinical practiceDoes my patient with a serum monoclonal spike have multiple myeloma?Many multiple myelomas: making more of the molecular mayhemMultiple myeloma: 2014 Update on diagnosis, risk-stratification, and managementComparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsMolecular pathogenesis of multiple myeloma: basic and clinical updatesTowards Stratified Medicine in Plasma Cell MyelomaMolecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapiesDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesPomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM).Phase 2 trial of intravenously administered plerixafor for stem cell mobilization in patients with multiple myeloma following lenalidomide-based initial therapy.Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomibRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myelomaImpact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Multiple myeloma patients at various cytogenetic risks benefit differently from autologous stem cell transplantation as a consolidation therapyChromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialTrends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisReduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survivalApproach to the treatment of multiple myeloma: a clash of philosophies.Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasoneChronic hepatitis virus infection in patients with multiple myeloma: clinical characteristics and outcomes.Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.MicroC(3): an ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells.Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaGenetic markers used for risk stratification in multiple myeloma.European perspective on multiple myeloma treatment strategies: update following recent congressesCurative one-shot systemic virotherapy in murine myeloma.Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tidesClonal competition with alternating dominance in multiple myeloma.A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents.The high cost of cancer drugs and what we can do about it.Multiple Myeloma: Treatment is Getting Individualized
P2860
Q26771331-A2F7669B-D9D8-4721-8AB6-69A37186B62BQ26777803-9B82A1DE-67AB-4B6C-ABBF-EAB42A277495Q26821981-11A0940E-BB32-4249-9D43-54F63E76A913Q26852892-ED8BCF11-1728-44F9-AA0E-71E83D9A39AFQ26998884-A3DF232A-DD27-4BD6-ADD6-EF7E46A02257Q27024932-CD4F61AE-B64C-48C8-AE00-52CCD4EC6267Q27026205-A9499C36-3540-4C0A-9B86-F2C15A87B5E9Q28074994-21E37EE1-21DA-4127-8787-54187D0E70F7Q28079232-F80662D8-1922-422D-893A-4EF6D321917AQ28290236-486CF6C4-0BF1-42F3-AD6B-6E1904F53FF3Q33391803-ED458D64-73DA-4A7A-B17E-756CA9B4AB03Q33411277-A7453F1A-11F9-4CF1-BC5C-2EFD75EAC94BQ33415759-5127578D-9A36-4D3B-807B-FE7079723D8BQ33425190-DC1C9413-B812-4855-A7CB-37BDA5BB1C83Q33942495-F10ACA57-7E21-40A2-86D1-42A5F80FA84CQ34008600-EB29AE37-42F0-4240-A386-6F5E82F13F03Q34115051-919EC7F0-DDCE-402E-90D1-BA78EDBE16FBQ34316917-9CC04F5C-915C-4B11-964D-BEFFF651A6F6Q34450910-A15B7962-3388-41B1-9C06-FA74027C02BEQ35061518-62FC9A87-4031-4811-B898-42A2B9DF0607Q35097105-15C9D1D6-4FAD-4400-8A0E-B3DA82E06011Q35141814-4CDA451D-C769-4AAB-AA72-267D46D06728Q35172500-68F51FCB-4FBA-4116-8A35-F1B09268B916Q35212337-0B5C202A-D898-476A-923E-253B0BB4CC95Q35230189-29CA7390-7D28-42A4-9664-9403CB751EBDQ35485758-64260B1C-545E-4C52-A185-3EB69973AFBAQ35580212-7A5C51BF-3986-4F4D-981A-408C0EE13DD0Q35685454-B34E2BE7-C4F1-4019-BEA3-68CBABA40DF7Q35700723-AD54BA62-6612-4FAC-B694-E29CDB4D0ABAQ35766816-E3EB60D9-0FDF-4EAA-BAC7-644820F37E05Q35849219-B6D90145-5E7B-419F-BA07-40B02ED2CD39Q35907767-3C32F109-9D81-47B6-8761-9D91E8CA144CQ35910262-4CCDD238-5A9E-42CD-904C-DF3998D5866EQ35989943-7ADF5AEB-7918-4974-889D-E9F7555B4256Q36139716-50FFC19E-C885-4156-B784-35ECEC6F1703Q36141838-98CC4B41-20F0-4382-A9B5-06DEED30090FQ36141846-90562CBD-78F8-454F-BEC9-D9CABE189FAEQ36449801-F8BC4B1E-CA7F-40EF-A779-96290D4CF78AQ36512856-3246EC58-1548-4A49-8935-F3C6A7429C17Q36522964-D621B6A0-E462-4F37-A7A8-83E04F83B361
P2860
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of newly diagnosed ...... (mSMART) consensus guidelines
@en
Management of newly diagnosed ...... eloma and Risk-Adapted Therapy
@nl
type
label
Management of newly diagnosed ...... (mSMART) consensus guidelines
@en
Management of newly diagnosed ...... eloma and Risk-Adapted Therapy
@nl
prefLabel
Management of newly diagnosed ...... (mSMART) consensus guidelines
@en
Management of newly diagnosed ...... eloma and Risk-Adapted Therapy
@nl
P2093
P2860
P50
P356
P1476
Management of newly diagnosed ...... (mSMART) consensus guidelines
@en
P2093
A Keith Stewart
Craig B Reeder
Francis K Buadi
John A Lust
Joseph R Mikhael
Kristen E Detweiler Short
P Leif Bergsagel
Philip R Greipp
Rafael Fonseca
Robert J Dalton
P2860
P304
P356
10.4065/MCP.2009.0603
P407
P50
P577
2009-12-01T00:00:00Z